Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial

Silvio Danese, Remo Panaccione, Brian G. Feagan, Anita Afzali, David T. Rubin, Bruce E. Sands, Walter Reinisch, Julián Panés, Aparna Sahoo, Natalie A. Terry, Daphne Chan, Chenglong Han, Mary Ellen Frustaci, Zijiang Yang, William J. Sandborn, Tadakazu Hisamatsu, Jane M. Andrews, Geert D’Haens, Oleksandr Oliinyk, Leonid Bilіanskyi, Jadwiga Gniady-Jastrzebska, Robert Petryka, Tomasz Arłukowicz, Piotr Gietka, Marcin Zmudziński, Syed Mumtaz, Douglas C. Wolf, Katarzyna Wójcik‐Pszczoła, George Duvall, Monika Augustyn, Rafał Filip, Dino Tarabar, Tkachev Av, Ursula Seidler, Eran Zittan, Juris Pokrotnieks, О. Б. Щукина, Andro Machavariani, Laura Loy, Niazy Abu-farsakh, Pesegova Marina, Slobodan Srećković, Martin Laclav, Shu‐Chen Wei, Daniel Suiter, A Borsuk, Xavier Hébuterne, Carsten Büning, Adi Lahat-Zok, Wit Danilkiewicz, Bernadetta Frysna, Ivana Jovicic, Olena Datsenko, Maninder Guram, Animesh Jain, Zahid Rashid, Sonja Heeren, Natallia Shulga, Ivan Timkin, Srdjan Gornjakovic, Milan Lukáš, Romain Altwegg, Ariadne Desjeux, Jean‐Marie Reimund, Manana Giorgadze, Christoph Jochum, Hiroaki Ito, Katsuhiko Nakai, Tomohisa Takagi, Osamu Zaha, Chang‐Hwan Choi, Taeoh Kim, Jong Hun Lee, Ieva Stundienė, Ida Hilmi, Rosaida Hj Md Said, Jarosław Leszczyszyn, Д. И. Абдулганиева, Yu. A. Fominykh, Svetlana V Maksyashina, Jozef Baláž, Manuel Van Domselaar, Taylan Kav, Patrick Dennis, Patricia Henry, Robert Holmes, Christopher M. Johnson, Matthew J. McBride, H Sarles, Gregory Moore, R. E. Yakubtsevich, Vinciane Muls, Stevan Trbojević, Waqqas Afif, Çharles N. Bernstein, Ivo Klarin, Zuzana Šerclová, Miroslava Volfová, Pierre Desreumaux, Cyrielle Gilletta2023 · DOI

This summary provides a technical overview of the maintenance results from the GALAXI-1 trial, recently published in The Lancet Gastroenterology & Hepatology.

TL;DR

The Phase 2 GALAXI-1 trial demonstrates that guselkumab, a selective IL-23 p19 subunit antagonist, provides durable clinical and endoscopic efficacy through 48 weeks in patients with moderately to severely active Crohn’s disease. Notably, the study utilized a "treat-through" design, showing that even some initial non-responders achieved clinical remission with continued treatment, all while maintaining a favorable safety profile.

What Problem Does This Paper Address?

Crohn’s disease (CD) is a chronic, debilitating inflammatory bowel disease. While several biological classes exist—including TNF antagonists, integrin antagonists, and IL-12/23 inhibitors—many patients either never respond (primary non-response) or lose response over time (secondary loss of response).

There is a critical need for therapies that offer higher "ceilings" of efficacy, particularly regarding mucosal healing (endoscopic remission), which is a strong predictor of long-term positive outcomes. Guselkumab is unique because it not only binds the p19 subunit of IL-23 with high affinity but also binds the CD64 receptor on inflammatory monocytes, potentially neutralizing IL-23 at its primary source within inflamed tissues.

Methods

GALAXI-1 was a Phase 2, randomized, double-blind, multicenter trial. The study employed a "treat-through" design, which differs from the "re-randomized" design common in many IBD trials. In a treat-through study, patients remain on their assigned induction therapy through the maintenance phase regardless of their early response, allowing researchers to observe "slow responders."

Treatment Arms: 1. Guselkumab 200→100 mg: 200 mg IV at weeks 0, 4, 8; then 100 mg SC every 8 weeks. 2. Guselkumab 600→200 mg: 600 mg IV at weeks 0, 4, 8; then 200 mg SC every 4 weeks. 3. Guselkumab 1200→200 mg: 1200 mg IV at weeks 0, 4, 8; then 200 mg SC every 4 weeks. 4. Ustekinumab (Reference): ~6 mg/kg IV induction, then 90 mg SC every 8 weeks. 5. Placebo: Induction placebo, with responders continuing placebo and non-responders crossing over to ustekinumab at week 12.

The primary efficacy analysis population included 309 patients, stratified by baseline disease activity and prior biologic failure.

Datasets

The study analyzed data from 309 patients in the primary efficacy analysis population and 360 patients in the safety population. The cohort was diverse:

  • Biologic-naive: 112 patients.
  • Biologic-experienced: 197 patients (a "difficult-to-treat" group).
  • Geography: 128 centers globally.

Key Insights and Ideas

  • The Value of Persistence: A key "aha moment" came from the treat-through design. Among patients who did not have a clinical response to guselkumab at week 12, nearly half (46%) achieved a clinical response by week 24, and 41% were in clinical remission by week 48. This suggests that for some patients, the standard 12-week induction window may be too short to judge a drug's ultimate success.
  • Deep Healing: Guselkumab showed impressive rates of endoscopic remission (SES-CD score ≤2). At week 48, up to 33% of patients in the highest dose group achieved endoscopic remission, compared to only 6% in the ustekinumab reference group (though the study wasn't powered for formal comparison).
  • Mechanistic Synergy: The authors hypothesize that guselkumab’s dual binding (IL-23 p19 and CD64) may enrich the drug's presence in the inflamed microenvironment, contributing to the observed mucosal healing.

Key Results

  • Clinical Remission (CDAI <150): At week 48, remission rates were 64%, 73%, and 57% across the three guselkumab groups, respectively.
  • Endoscopic Response (≥50% improvement): Rates were 44%, 46%, and 44% for the guselkumab groups, compared to 30% for the ustekinumab reference group.
  • Safety: Guselkumab was well-tolerated. The most common adverse events were nasopharyngitis and upper respiratory infections. No cases of active tuberculosis, opportunistic infections, or deaths occurred through week 48.
  • Bio-Experienced Success: Even in patients who had failed prior biologics, guselkumab maintained high rates of clinical remission and endoscopic response.

Limitations and Future Work

  • Phase 2 Constraints: As a Phase 2 study, it was not powered to perform formal statistical comparisons between the different guselkumab doses or against the ustekinumab reference arm.
  • Placebo Comparison: Because most placebo non-responders crossed over to active treatment at week 12, the long-term placebo "maintenance" group was very small (n=15), limiting the ability to draw comparative conclusions at week 48.
  • Phase 3 Transition: These results served as the foundation for the ongoing Phase 3 GALAXI-2 and GALAXI-3 trials, which will provide the definitive evidence required for regulatory approval and broader clinical use.

Summary updated

BibTeX
@inproceedings{danese2023efficacy,
  author = {Silvio Danese and Remo Panaccione and Brian G. Feagan and Anita Afzali and David T. Rubin and Bruce E. Sands and Walter Reinisch and Julián Panés and Aparna Sahoo and Natalie A. Terry and Daphne Chan and Chenglong Han and Mary Ellen Frustaci and Zijiang Yang and William J. Sandborn and Tadakazu Hisamatsu and Jane M. Andrews and Geert D’Haens and Oleksandr Oliinyk and Leonid Bilіanskyi and Jadwiga Gniady-Jastrzebska and Robert Petryka and Tomasz Arłukowicz and Piotr Gietka and Marcin Zmudziński and Syed Mumtaz and Douglas C. Wolf and Katarzyna Wójcik‐Pszczoła and George Duvall and Monika Augustyn and Rafał Filip and Dino Tarabar and Tkachev Av and Ursula Seidler and Eran Zittan and Juris Pokrotnieks and О. Б. Щукина and Andro Machavariani and Laura Loy and Niazy Abu-farsakh and Pesegova Marina and Slobodan Srećković and Martin Laclav and Shu‐Chen Wei and Daniel Suiter and A Borsuk and Xavier Hébuterne and Carsten Büning and Adi Lahat-Zok and Wit Danilkiewicz and Bernadetta Frysna and Ivana Jovicic and Olena Datsenko and Maninder Guram and Animesh Jain and Zahid Rashid and Sonja Heeren and Natallia Shulga and Ivan Timkin and Srdjan Gornjakovic and Milan Lukáš and Romain Altwegg and Ariadne Desjeux and Jean‐Marie Reimund and Manana Giorgadze and Christoph Jochum and Hiroaki Ito and Katsuhiko Nakai and Tomohisa Takagi and Osamu Zaha and Chang‐Hwan Choi and Taeoh Kim and Jong Hun Lee and Ieva Stundienė and Ida Hilmi and Rosaida Hj Md Said and Jarosław Leszczyszyn and Д. И. Абдулганиева and Yu. A. Fominykh and Svetlana V Maksyashina and Jozef Baláž and Manuel Van Domselaar and Taylan Kav and Patrick Dennis and Patricia Henry and Robert Holmes and Christopher M. Johnson and Matthew J. McBride and H Sarles and Gregory Moore and R. E. Yakubtsevich and Vinciane Muls and Stevan Trbojević and Waqqas Afif and Çharles N. Bernstein and Ivo Klarin and Zuzana Šerclová and Miroslava Volfová and Pierre Desreumaux and Cyrielle Gilletta},
  title = {{Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial}},
  booktitle = {˜The},
  year = {2023},
  doi = {10.1016/s2468-1253(23)00318-7},
}
Figure